OrthoPediatrics Sees ‘Inflection Point' as New Products Fuel Record Quarter
OrthoPediatrics NASDAQ: KIDS reported record revenue, adjusted EBITDA and number of children helped during the second quarter, as the pediatric orthopedic device company began to see early contributions from its newer “super cycle” products, Chief Executive Officer Dave Bailey said at the Canaccord Genuity Growth Conference.
OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript
OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript
OrthoPediatrics Q2 Earnings Call Highlights
OrthoPediatrics NASDAQ: KIDS reported record second-quarter revenue of $70.5 million, up 15% from a year earlier, as strong Trauma & Deformity and specialty bracing performance offset a reported decline in scoliosis revenue. The company also raised its 2026 revenue outlook while maintaining its adjusted EBITDA and free-cash-flow targets.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.11 per share a year ago.
OrthoPediatrics Corp. (KIDS) Q1 2026 Earnings Call Transcript
OrthoPediatrics Corp. (KIDS) Q1 2026 Earnings Call Transcript
OrthoPediatrics (KIDS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for OrthoPediatrics (KIDS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
OrthoPediatrics (KIDS) Reports Q1 Loss, Beats Revenue Estimates
OrthoPediatrics (KIDS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.39 per share a year ago.
Wall Street Analysts Predict a 51.12% Upside in OrthoPediatrics (KIDS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 51.1% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OrthoPediatrics (KIDS) Upgraded to Buy: What Does It Mean for the Stock?
OrthoPediatrics (KIDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 32.67% Upside in OrthoPediatrics (KIDS): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 32.7% in OrthoPediatrics (KIDS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OrthoPediatrics Corp. (KIDS) Q4 2025 Earnings Call Transcript
OrthoPediatrics Corp. (KIDS) Q4 2025 Earnings Call Transcript
OrthoPediatrics (KIDS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for OrthoPediatrics (KIDS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
